

Dragana Nikolic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2190089/publications.pdf>

Version: 2024-02-01

9
papers

445
citations

1307366

7
h-index

1474057

9
g-index

9
all docs

9
docs citations

9
times ranked

768
citing authors

#	ARTICLE	IF	CITATIONS
1	Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. <i>Diabetes Therapy</i> , 2021, 12, 261-274.	1.2	41
2	Preliminary Results of CitraVesâ,ç Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study. <i>Metabolites</i> , 2021, 11, 276.	1.3	18
3	Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 241-244.	0.9	2
4	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. <i>Cardiovascular Diabetology</i> , 2016, 15, 162.	2.7	98
5	Can the effects of gender, menopause and ageing on lipid levels be differentiated?. <i>Clinical Endocrinology</i> , 2016, 85, 694-695.	1.2	2
6	The effect of bergamot on dyslipidemia. <i>Phytomedicine</i> , 2016, 23, 1175-1181.	2.3	35
7	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 453-461.	2.2	64
8	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 353-368.	2.2	61
9	Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. <i>Nutrients</i> , 2013, 5, 928-948.	1.7	124